TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33222803

Group type: EXPERIMENTAL
Intervention: Oral tenofovir disoproxil fumarate and emtricitabine for PrEP, taken daily for the first 12 weeks.
Number of subjects: 148
Study: 33223114

Group type: EXPERIMENTAL
Intervention: Secondary infections (BSIs and pLRTIs)
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Overall incidence of secondary infections
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Types of pathogens causing BSIs
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Types of pathogens causing pLRTIs
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Risk factors for secondary infections
Number of subjects: 731
Study: 33224273

Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device (PED) alone
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device (PED) plus coiling
Number of subjects: 1171

Group type: COMPARATOR
Intervention: Pipeline Embolization Device (PED)
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Predictors of aneurysm occlusion
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: In-stent stenosis predictors
Number of subjects: 1171
Study: 33224623

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT imaging
Number of subjects: 33
Study: 33224628

Group type: EXPERIMENTAL
Intervention: SAR439459 (pan-TGFβ neutralizing antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of SAR439459 with anti-PD-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SAR439459
Number of subjects: 0
Study: 33224753

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (once daily)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Dabigatran (twice daily)
Number of subjects: 271
Study: 33224806

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone (treatment group, n=41)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (control group, n=40)
Number of subjects: 81
Study: 33225383

Group type: EXPERIMENTAL
Intervention: Living in an institution
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Impaired Activity of Daily Living scale score
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: HbA1c ≥ 70 mmol/mol
Number of subjects: 987
Study: 33225410

Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF) 240 mg twice daily
Number of subjects: 231
Study: 33225717

Group type: EXPERIMENTAL
Intervention: Oral glucose intake during an oral glucose tolerance test, assessed by indirect calorimetry for measuring diet-induced thermogenesis (DIT).
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cold exposure for 2 hours to assess cold-induced thermogenesis (CIT).
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Assessment of maximum brown adipose tissue (BAT) activity using 18-F-fluoro-deoxyglucose.
Number of subjects: 17
Study: 33225826

Group type: EXPERIMENTAL
Intervention: Cordycepin
Number of subjects: 0
Study: 33225915

Group type: EXPERIMENTAL
Intervention: Healthy Together (HT) program
Number of subjects: 663
Study: 33225917

Group type: EXPERIMENTAL
Intervention: Home haemodialysis (HHD)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional in-centre haemodialysis (ICHD)
Number of subjects: 160
Study: 33225952

Group type: EXPERIMENTAL
Intervention: High-dose thromboprophylaxis (≥ 175 IU/kg of body weight tinzaparin or ≥ 200 IU/kg of body weight dalteparin)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Medium-dose thromboprophylaxis (> 4500 IU but < 175 IU/kg of body weight tinzaparin or > 5000 IU but < 200 IU/kg of body weight dalteparin)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Low-dose thromboprophylaxis (2500-4500 IU tinzaparin or 2500-5000 IU dalteparin)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: High-dose thromboprophylaxis
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Medium-dose thromboprophylaxis
Number of subjects: 152

Group type: COMPARATOR
Intervention: Low-dose thromboprophylaxis
Number of subjects: 152
Study: 33226334

Group type: EXPERIMENTAL
Intervention: Opioid use (measured in lowest recommended dosage units)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Sleep parameters (actigraphy/self-reported total wake time and self-reported sleep quality)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Evening pain
Number of subjects: 65
Study: 33226548

Group type: EXPERIMENTAL
Intervention: DAILY EATS questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eating Drivers Index (EDI) derived from DAILY EATS items
Number of subjects: 0
Study: 33226632

Group type: EXPERIMENTAL
Intervention: Individualized fortification (targeted or adjustable)
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Targeted fortification
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Adjustable fortification
Number of subjects: 521

Group type: COMPARATOR
Intervention: Standard non-individualized fortification
Number of subjects: 521
Study: 33227125

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg/d
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg/d (prior RTX treatment)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg/d (prior RTX-CIT treatment)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg/d (extranodal subtype)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg/d (nodal subtype)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg/d (splenic subtype)
Number of subjects: 63
Study: 33227153

Group type: EXPERIMENTAL
Intervention: Non-invasive haemoglobin measurement
Number of subjects: 0
Study: 33227283

Group type: EXPERIMENTAL
Intervention: Thiopurines (n=242)
Number of subjects: 1490

Group type: EXPERIMENTAL
Intervention: Biologics (n=642)
Number of subjects: 1490

Group type: EXPERIMENTAL
Intervention: Combination therapy (n=227)
Number of subjects: 1490

Group type: COMPARATOR
Intervention: Unexposed (n=379)
Number of subjects: 1490

Group type: EXPERIMENTAL
Intervention: Higher disease activity
Number of subjects: 1490
Study: 33227350

Group type: EXPERIMENTAL
Intervention: Proven bacterial infections
Number of subjects: 1273

Group type: EXPERIMENTAL
Intervention: Severe alcoholic hepatitis
Number of subjects: 1273

Group type: EXPERIMENTAL
Intervention: Adequate first-line antibiotic treatment of proven bacterial infections
Number of subjects: 1273

Group type: EXPERIMENTAL
Intervention: Number of precipitants
Number of subjects: 1273
Study: 33227397

Group type: EXPERIMENTAL
Intervention: Clinicians often wondering about the appropriateness of a resuscitation attempt
Number of subjects: 5099

Group type: EXPERIMENTAL
Intervention: Clinicians experiencing moral distress caused by inappropriate CPR
Number of subjects: 5099

Group type: EXPERIMENTAL
Intervention: Clinicians aged 30-44 years
Number of subjects: 5099

Group type: COMPARATOR
Intervention: Clinicians feeling valued by the team
Number of subjects: 5099

Group type: COMPARATOR
Intervention: Clinicians in teams where the team leader acknowledged efforts
Number of subjects: 5099

Group type: COMPARATOR
Intervention: Clinicians in teams that took time for debriefing
Number of subjects: 5099
Study: 33227457

Group type: EXPERIMENTAL
Intervention: Chronic venous disease (C3 and C5 limbs)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 57
Study: 33228537

Group type: EXPERIMENTAL
Intervention: mTBI patients with APTH
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: mTBI patients developing chronic posttraumatic headache (CPTH)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 77
Study: 33228724

Group type: EXPERIMENTAL
Intervention: Pregnancy HEI-total
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postpartum HEI-total
Number of subjects: 0
Study: 33228771

Group type: EXPERIMENTAL
Intervention: Home birth fecal supernatants
Number of subjects: 180

Group type: COMPARATOR
Intervention: C-section infants
Number of subjects: 180
Study: 33228796

Group type: EXPERIMENTAL
Intervention: Caregiver's relationship to the patient (more parents were the caregiver in females than in males)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Caregiver's employment situation (more employed caregivers in females)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Economic situation of patients
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Social support perception
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Partner relationship perception
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Functional status of families
Number of subjects: 333
Study: 33228797

Group type: EXPERIMENTAL
Intervention: Miglustat (part of routine clinical care)
Number of subjects: 36

Group type: COMPARATOR
Intervention: NPC population
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 5-domain NPCCSS
Number of subjects: 36
Study: 33228978

Group type: EXPERIMENTAL
Intervention: Change in plasma tau from preoperative concentrations to postoperative Day 1
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Change in tau
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Tau changes
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Tau
Number of subjects: 114
Study: 33229343

Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN1) for classification of B-scans containing retinal cavitations
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN2) for segmentation of retinal cavitations
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Proposed method for measuring retinal cavitation volume
Number of subjects: 67
Study: 33229362

Group type: EXPERIMENTAL
Intervention: Rilonacept 320 mg SC load/160 mg SC weekly maintenance
Number of subjects: 25
Study: 33229456

Group type: EXPERIMENTAL
Intervention: LY3300054 monotherapy
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: LY3300054 combined with ramucirumab
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: LY3300054 combined with abemaciclib
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: LY3300054 combined with merestinib
Number of subjects: 4
Study: 33229508

Group type: EXPERIMENTAL
Intervention: Expanded CD4 T cells cultured with high dose of interleukin-2 for up to 5 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Expanded CD4 T cells with TIM-3 expression
Number of subjects: 23
Study: 33229715

Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Weight-bearing walking training (Kunming Locomotion Training Program - KLTP) for 6 months
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Weight-bearing walking training (KLTP)
Number of subjects: 320
Study: 33229973

Group type: EXPERIMENTAL
Intervention: Steroid encapsulating polymeric microparticles for longer lasting pain relief
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrically charged biomaterials for intra-cartilage targeting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viral vectors for gene therapy
Number of subjects: 0
Study: 33230035

Group type: EXPERIMENTAL
Intervention: Compensation training and substitution therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive training inside the blind field
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Earlier intervention and advanced training procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noninvasive brain stimulation and pharmacological adjuvants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive rehabilitative strategies
Number of subjects: 0
Study: 33230103

Group type: EXPERIMENTAL
Intervention: CD19-specific chimeric antigen receptor T cell (CD19 CAR T) therapy
Number of subjects: 51
Study: 33230210

Group type: EXPERIMENTAL
Intervention: peposertib 100-200 mg once daily or 150-400 mg twice daily (BID) in 21-day cycles
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: peposertib 400 mg BID (RP2D)
Number of subjects: 31
Study: 33230959

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 30
Study: 33230961

Group type: EXPERIMENTAL
Intervention: Higher-weight-loss responders (HWLRs) with ≥20% total body weight loss (TBWL) at 5 years after MBS
Number of subjects: 192

Group type: COMPARATOR
Intervention: Lower-weight-loss responders (LWLRs) with <20% total body weight loss (TBWL) at 5 years after MBS
Number of subjects: 192
Study: 33230962

Group type: EXPERIMENTAL
Intervention: Ketosis (βHB: 1.24±0.82 mmol/L in fasting)
Number of subjects: 87
Study: 33231108

Group type: EXPERIMENTAL
Intervention: Event-specific win ratios
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum test based on event-specific win ratios
Number of subjects: 0
Study: 33231487

Group type: EXPERIMENTAL
Intervention: ACE-I/ARB therapy
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: ACE-I/ARB therapy during hospitalization
Number of subjects: 338
Study: 33231550

Group type: EXPERIMENTAL
Intervention: MoMba Live Long system (smartphone-based breath carbon monoxide meter)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Commercial monitor (piCO)
Number of subjects: 10
Study: 33231556

Group type: EXPERIMENTAL
Intervention: Inhibition (Stroop-like exercises)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Updating (N-back-type exercises)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control active (quiz game exercise)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Inhibition and Updating
Number of subjects: 90
Study: 33231559

Group type: EXPERIMENTAL
Intervention: Responsive Parenting (RP) intervention
Number of subjects: 131
Study: 33231709

Group type: EXPERIMENTAL
Intervention: Group III (HbA1c ≥6.5%)
Number of subjects: 27337

Group type: COMPARATOR
Intervention: Group I (HbA1c <5.7%)
Number of subjects: 27337

Group type: EXPERIMENTAL
Intervention: Group II (HbA1c 5.7-6.4%)
Number of subjects: 27337
Study: 33232306

Group type: EXPERIMENTAL
Intervention: Administration or optogenetic stimulation of vasopressin in the lateral septum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 33232348

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing techniques
Number of subjects: 15

Group type: COMPARATOR
Intervention: Current practices in oncology (without Motivational Interviewing)
Number of subjects: 15
Study: 33232473

Group type: EXPERIMENTAL
Intervention: Recombinant FVIII
Number of subjects: 0
Study: 33232483

Group type: COMPARATOR
Intervention: PsO
Number of subjects: 104

Group type: COMPARATOR
Intervention: PsA
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: PsA and PsO
Number of subjects: 104
Study: 33232518

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 3738

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 3738

Group type: EXPERIMENTAL
Intervention: Misoprostol plus oxytocin
Number of subjects: 3738
Study: 33232613

Group type: EXPERIMENTAL
Intervention: Turkish version of the neurogenic bladder symptom score (NBSS)
Number of subjects: 102
Study: 33234490

Group type: EXPERIMENTAL
Intervention: Nivolumab and Temozolomide
Number of subjects: 0
Study: 33234626

Group type: EXPERIMENTAL
Intervention: Extended ICF Checklist V.2.1a
Number of subjects: 65
Study: 33234643

Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM) group
Number of subjects: 980

Group type: COMPARATOR
Intervention: Control group (offspring of healthy mothers)
Number of subjects: 980
Study: 33234651

Group type: EXPERIMENTAL
Intervention: Serological tests for COVID-19 (IgM and IgG antibodies)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control cohort (prepandemic time)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Measurement of IgM and IgG antibodies
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Assessment of false negative PCR tests
Number of subjects: 400
Study: 33234656

Group type: EXPERIMENTAL
Intervention: Predi-COVID participants
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Predi-COVID-H participants
Number of subjects: 500
Study: 33234662

Group type: EXPERIMENTAL
Intervention: Combination of tumour infiltrating lymphocytes (TIL) and anti-PD-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of TIL, pegylated-interferon-alpha (PEG-IFNa) and anti-PD-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Efficacy evaluation in phase II
Number of subjects: 0
Study: 33234944

Group type: EXPERIMENTAL
Intervention: Insulin-treated diabetes
Number of subjects: 36762

Group type: EXPERIMENTAL
Intervention: Orally treated diabetes
Number of subjects: 36762

Group type: EXPERIMENTAL
Intervention: Dietary-treated diabetes
Number of subjects: 36762

Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 36762
Study: 33235353

Group type: EXPERIMENTAL
Intervention: Donor-derived anti-CD19 CAR T cells
Number of subjects: 28

Group type: COMPARATOR
Intervention: DLI
Number of subjects: 28
Study: 33235468

Group type: EXPERIMENTAL
Intervention: Irinotecan-containing regimen
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Chemotherapeutic regimen (oxaliplatin-containing or irinotecan-containing)
Number of subjects: 264
Study: 33235733

Group type: EXPERIMENTAL
Intervention: Oncoxin-Viusid (OV)
Number of subjects: 25
Study: 33235971

Group type: EXPERIMENTAL
Intervention: GLB+NGx (modified Group Lifestyle Balance with nutrigenomics)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard GLB (Group Lifestyle Balance)
Number of subjects: 140
Study: 33235996

Group type: EXPERIMENTAL
Intervention: Stereotactic conformal radiotherapy (SCRT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional radiotherapy (ConvRT)
Number of subjects: 200
Study: 33236064

Group type: EXPERIMENTAL
Intervention: Self-reported sleep quality (PSQI #1)
Number of subjects: 2205

Group type: EXPERIMENTAL
Intervention: Self-reported sleep disturbances (PSQI #5)
Number of subjects: 2205

Group type: EXPERIMENTAL
Intervention: Self-reported sleep parameters
Number of subjects: 2205
Study: 33236084

Group type: EXPERIMENTAL
Intervention: Index offspring (mothers with T1D)
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: IGF-1
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Lean mass
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Interaction between IR and IGF-1
Number of subjects: 581
Study: 33236783

Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 333
Study: 33236943

Group type: EXPERIMENTAL
Intervention: Navitoclax
Number of subjects: 0
Study: 33237035

Group type: EXPERIMENTAL
Intervention: BLS serious game module
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hands-on training app
Number of subjects: 25

Group type: COMPARATOR
Intervention: OSCE scores
Number of subjects: 25
Study: 33237037

Group type: EXPERIMENTAL
Intervention: Digital Bridge (using Care Connector and ePRO)
Number of subjects: 600
Study: 33237291

Group type: EXPERIMENTAL
Intervention: Chilblain-like lesions patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Patients with mild-severe acute COVID-19
Number of subjects: 40
Study: 33237355

Group type: EXPERIMENTAL
Intervention: Physiotherapist-supervised pelvic floor muscle training (PFMT) over 12 weeks, including six physiotherapy sessions and a home PFMT program.
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Predictors of cure identified through binary logistic regression model: ICIQ-UI-SF, PFM tone, bladder neck (BN) height in a quiet standing position, and BN height during a cough in a standing position.
Number of subjects: 77
Study: 33237534

Group type: EXPERIMENTAL
Intervention: INL-001 implants (3 implants, each containing 100 mg bupivacaine HCl)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.25% bupivacaine HCl infiltration (175 mg)
Number of subjects: 50
Study: 33238029

Group type: EXPERIMENTAL
Intervention: Transanal hemorrhoidal dearterialization (THD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ferguson hemorrhoidectomy
Number of subjects: 10
Study: 33238043

Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks (PNBs)
Number of subjects: 3061

Group type: COMPARATOR
Intervention: No nerve block (or sham block)
Number of subjects: 3061
Study: 33238176

Group type: EXPERIMENTAL
Intervention: Lifestyle interventions (diet and physical activity)
Number of subjects: 1148

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1148

Group type: EXPERIMENTAL
Intervention: Lifestyle interventions
Number of subjects: 1148

Group type: COMPARATOR
Intervention: Lifestyle interventions and Standard care
Number of subjects: 1148
Study: 33238584

Group type: EXPERIMENTAL
Intervention: Lower household income
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Higher household crowding
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Maternal secondary education
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Maternal higher education
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Participation in Bolsa Família social protection programme
Number of subjects: 163
Study: 33238728

Group type: EXPERIMENTAL
Intervention: Stroke Ready Very Brief Intervention
Number of subjects: 0
Study: 33238908

Group type: EXPERIMENTAL
Intervention: GERO cohort intervention (multidimensional evaluation including socio-demographic, biomedical, psychosocial, neuropsychological, neuropsychiatric, and motor assessments)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Telephone interviews at months 6, 12, 24, and 30
Number of subjects: 300
Study: 33238944

Group type: EXPERIMENTAL
Intervention: Toluidine blue (TB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Frozen section (FS)
Number of subjects: 30
Study: 33239013

Group type: EXPERIMENTAL
Intervention: 10g vital wheat gluten (low in FODMAPs) in 100ml water
Number of subjects: 295
Study: 33239053

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33239056

Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 46
Study: 33239079

Group type: EXPERIMENTAL
Intervention: 12-week RSTEP HIIT program, 2-3 times per week, 10 cycles of 60-s intervals at 90% VO
Number of subjects: 15
Study: 33239124

Group type: EXPERIMENTAL
Intervention: Mask use adherence
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Absenteeism due to influenza symptoms
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Presenteeism with respiratory symptoms
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Influenza symptom reporting
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Influenza virus shedding
Number of subjects: 152
Study: 33239226

Group type: EXPERIMENTAL
Intervention: 1-dose Havrix vaccine
Number of subjects: 600

Group type: COMPARATOR
Intervention: 2-dose Havrix vaccine
Number of subjects: 600
Study: 33239228

Group type: EXPERIMENTAL
Intervention: qHPV vaccine (3 doses on Day 1, Month 2, Month 6)
Number of subjects: 766
Study: 33239386

Group type: EXPERIMENTAL
Intervention: GD2-directed CAR-T cells
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Preparative lymphodepletion
Number of subjects: 12